Targeted drug plus chemo takes on hard-to-treat pancreatic cancer
NCT ID NCT06892054
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This early-stage trial tests whether adding the targeted drug sotorasib to standard chemotherapy is safe for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. About 15 adults will receive the combination as their first treatment. The main goal is to check for side effects, with a secondary focus on how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Besançon - Hôpital Jean Minjoz
NOT_YET_RECRUITINGBesançon, France, France
Contact
-
Chu Bordeaux - Hôpital Haut Lévêque
NOT_YET_RECRUITINGPessac, France, France
Contact
-
Chu Brest - Hôpital Morvan
NOT_YET_RECRUITINGBrest, France, France
Contact
-
Chu Poitiers
NOT_YET_RECRUITINGPoitiers, France, France
Contact
-
Chu Reims - Hôpital Robert Debré
NOT_YET_RECRUITINGReims, France, France
Contact
-
Chu Toulouse
NOT_YET_RECRUITINGToulouse, France, France
Contact
-
Chu de Lille - Claude Huriez
NOT_YET_RECRUITINGLille, France, France
Contact
-
Complejo Hospitalario Regional de Málaga
RECRUITINGMálaga, Málaga, Spain
Contact
-
Complejo Hospitalario de Navarra
RECRUITINGPamplona, Navarre, Spain
Contact
-
Complexo Hospitalario Universitario de Ourense
RECRUITINGOurense, OURENSE, Spain
Contact
-
Hospital Clínic
RECRUITINGBarcelona, Barcelona, Spain
Contact
Contact
-
Hospital Clínico San Carlos
RECRUITINGMadrid, Madrid, Spain
Contact
-
Hospital General Universitario Gregorio Marañón
RECRUITINGMadrid, Madrid, Spain
Contact
-
Hospital General Universitario de Valencia
RECRUITINGValencia, Valencia, Spain
Contact
-
Hospital Reina Sofía
RECRUITINGCórdoba, Córdoba, Spain
Contact
-
Hospital Universitari Vall D'Hebron
RECRUITINGBarcelona, Barcelona, Spain
Contact
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Madrid, Spain
Contact
-
Hospital Universitario Central de Asturias
RECRUITINGOviedo, Principality of Asturias, Spain
Contact
-
Hospital Universitario Donostia-Donostia Unibertsitate Ospitalea
RECRUITINGDonostia / San Sebastian, Guipúzcoa, Spain
Contact
-
Hospital Universitario Marqués de Valdecilla
RECRUITINGSantander, Cantabria, Spain
Contact
-
Hospital Universitario Miguel Servet
RECRUITINGZaragoza, Aragon, Spain
Contact
-
Hospital Universitario de Salamanca
RECRUITINGSalamanca, SALAMANCA, Spain
Contact
-
Hôpital Léon Berard
NOT_YET_RECRUITINGLyon, France, France
Contact
-
Hôpital Paul-Brousse
NOT_YET_RECRUITINGVillejuif, France, France
Contact
-
Institut Català D'Oncologia L'Hospitalet (Ico)
RECRUITINGBarcelona, Barcelona, Spain
Contact
-
Sainte Catherine - Institut Avignon Provence
NOT_YET_RECRUITINGAvignon, France, France
Contact
Conditions
Explore the condition pages connected to this study.